Interferon-beta gene therapy for cancer: basic research to clinical application - PubMed (original) (raw)

Review

Interferon-beta gene therapy for cancer: basic research to clinical application

Jun Yoshida et al. Cancer Sci. 2004 Nov.

Abstract

Interferon-beta gene therapy for cancer is the first such protocol developed in Japan. Here we describe the development process of our interferon-beta gene therapy from basic research to clinical application. Interestingly, the biological and biochemical characteristics of interferon-beta gene therapy through transfer of the interferon-beta gene into tumor cells by means of cationic liposomes differed from those of conventional interferon-beta protein therapy. Interferon-beta gene transfer could induce apoptosis in interferon-beta protein-resistant tumor cells, such as glioma, melanoma, and renal cell carcinoma. Induction of apoptosis was related to the level of intracellular mRNA of interferon-beta, prolongation of the phosphorylation time of molecules in the interferon-beta signal transduction pathway, such as JAK1, Trk2, and STAT1, and activation of DNase gamma. In our preclinical study we developed lyophilized cationic liposomes containing interferon-beta gene (gene drug) for clinical use and confirmed their safety. Thereafter, we performed a pilot clinical trial in patients with malignant glioma and confirmed the safety and effectiveness of this interferon-beta gene therapy. In this review we also comment on the status of gene therapy regulation in Japan. Interferon-beta gene therapy is expected to become widely available for clinical use in cancer patients, and this new strategy might be extended to molecular targeting therapy, or used in combination with cell therapy or other therapies.

PubMed Disclaimer

Similar articles

• Basic study on gene therapy of human malignant glioma by use of the cationic multilamellar liposome-entrapped human interferon beta gene.
  Yagi K, Ohishi N, Hamada A, Shamoto M, Ohbayashi M, Ishida N, Nagata A, Kanazawa S, Nishikimi M. Yagi K, et al. Hum Gene Ther. 1999 Aug 10;10(12):1975-82. doi: 10.1089/10430349950017338. Hum Gene Ther. 1999. PMID: 10466631
• Clinical gene therapy for brain tumors. Liposomal delivery of anticancer molecule to glioma.
  Yoshida J, Mizuno M. Yoshida J, et al. J Neurooncol. 2003 Dec;65(3):261-7. doi: 10.1023/b:neon.0000003655.03671.fa. J Neurooncol. 2003. PMID: 14682376 Review.
• A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy.
  Wakabayashi T, Natsume A, Hashizume Y, Fujii M, Mizuno M, Yoshida J. Wakabayashi T, et al. J Gene Med. 2008 Apr;10(4):329-39. doi: 10.1002/jgm.1160. J Gene Med. 2008. PMID: 18220319 Clinical Trial.
• [Glioma].
  Wakabayashi T, Natsume A, Yoshida J. Wakabayashi T, et al. Nihon Rinsho. 2006 Jul;64(7):1327-32. Nihon Rinsho. 2006. PMID: 16838652 Review. Japanese.

Cited by

• Current status of non-viral gene therapy for CNS disorders.
  Jayant RD, Sosa D, Kaushik A, Atluri V, Vashist A, Tomitaka A, Nair M. Jayant RD, et al. Expert Opin Drug Deliv. 2016 Oct;13(10):1433-45. doi: 10.1080/17425247.2016.1188802. Epub 2016 Jun 1. Expert Opin Drug Deliv. 2016. PMID: 27249310 Free PMC article. Review.
• Cytokine-Enhanced Vaccine and Interferon-β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma.
  Finocchiaro LM, Fondello C, Gil-Cardeza ML, Rossi ÚA, Villaverde MS, Riveros MD, Glikin GC. Finocchiaro LM, et al. Hum Gene Ther. 2015 Jun;26(6):367-76. doi: 10.1089/hum.2014.130. Epub 2015 May 26. Hum Gene Ther. 2015. PMID: 25762364 Free PMC article. Clinical Trial.
• Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24.
  Ekmekcioglu S, Mumm JB, Udtha M, Chada S, Grimm EA. Ekmekcioglu S, et al. Cytokine. 2008 Jul;43(1):34-44. doi: 10.1016/j.cyto.2008.04.010. Epub 2008 Jun 3. Cytokine. 2008. PMID: 18511292 Free PMC article.
• Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.
  Wollmann G, Paglino JC, Maloney PR, Ahmadi SA, van den Pol AN. Wollmann G, et al. Virology. 2015 Jan 15;475:1-14. doi: 10.1016/j.virol.2014.10.035. Epub 2014 Nov 21. Virology. 2015. PMID: 25462341 Free PMC article.
• Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-beta.
  Micali OC, Cheung HH, Plenchette S, Hurley SL, Liston P, LaCasse EC, Korneluk RG. Micali OC, et al. BMC Cancer. 2007 Mar 21;7:52. doi: 10.1186/1471-2407-7-52. BMC Cancer. 2007. PMID: 17376236 Free PMC article.

References

1. 1. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JR, Ringold GM, Danielson M. Lipofection: a highly efficient, lipid‐medi‐ated DNA‐transfection procedure. Proc Natl Acad Sci USA 1987; 84: 7413–4. - PMC - PubMed
2. 1. Felgner RL, Ringold GM. Cationic liposome‐mediated transfection. Nature 1989; 337: 387–8. - PubMed
3. 1. Mizuno M, Yoshida J, Sugita K, Inoue I, Seo H, Hayashi Y, Koshizaka T, Yagi K. Growth inhibition of glioma cells transfected with the human β‐in‐terferon gene by liposomes coupled with a monoclonal antibody. Cancer Res 1990; 50: 7826–9. - PubMed
4. 1. Mizuno M, Yoshida J, Sugita K, Yagi K. Growth inhibition of glioma cells of different cell lines by human interferon‐(produced in the cells transfected with its gene by means of liposomes. J Clin Biochem. Nutr 1990; 9: 73–7.
5. 1. Yoshida J, Mizuno M, Yagi K. Secretion of human β‐interferon into the cystic fluid of glioma transfected with the interferon gene. J Clin Biochem Nutr 1991; 11: 123–8.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal